Companies Vying for Position with Psoriasis Drugs as Industry Sets to Double to Nearly $7 Billion in Next Decade
Recently, Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and health care issues, released an article stating that “the continued uptake of marketed and emerging interleukin and TNF-alpha inhibitors and a twofold increase in the penetration of biologics in the moderate-to-severe population will drive the psoriasis drug market to double from $3.4 billion in 2009 to $6.8 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan." The report went on to detail the main competitors in the psoriasis market which include: • Enbrel (etanercept), a TNF-alpha inhibitor (Amgen/GlaxoSmithKline/…